Result of AGM

Kromek Group PLC

28 September 2023

 

28 September 2023

Kromek Group plc

("Kromek" or the "Group")

Result of AGM

Kromek Group plc, a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its Annual General Meeting ("AGM"), held earlier today, all resolutions were duly passed.

Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:

Resolution	Votes for		Votes against		Votes withheld	Total proxy votes
	No. of votes	% of votes cast*	No. of votes	% of votes cast*	No. of votes
1	189,476,538	94.43	11,176,883	5.57	217,336	200,870,757
2	179,826,325	90.14	19,674,285	9.86	1,370,147	200,870,757
3	182,008,714	91.33	17,274,285	8.67	1,587,758	200,870,757
4	198,554,316	99.71	582,433	0.29	1,734,008	200,870,757
5	199,638,889	99.60	806,687	0.40	425,181	200,870,757
6	198,643,359	98.98	2,051,977	1.02	175,421	200,870,757
7	191,067,728	96.32	7,295,934	3.68	2,507,095	200,870,757
8	187,184,965	93.34	13,353,050	6.66	332,742	200,870,757

*Excludes withheld votes

For further information, please contact: 

Kromek Group plc
Arnab Basu, CEO  Paul Farquhar, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  Tim Redfern/Charlotte Sutcliffe - ECM	[phone]
Michael Johnson/Tamar Cranford-Smith - Sales
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble	[phone]

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

END